CD38 antibody plus steroid for acquired hemophilia A
Part of Blood & lymphatic clinical trials.
This trial studies whether a CD38-targeting antibody together with corticosteroids can improve outcomes in acquired hemophilia A. It is an “exploratory” Phase 4 study, meaning the goal is to learn more about safety and effectiveness in real-world patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acquired hemophilia A (not a different bleeding disorder).
- If you are female, you are either postmenopausal or able to have children and can use strict birth control during the study.
- You are expected to follow the study plan well and take treatments as required.
- You do not have congenital hemophilia with an inhibitor (a condition where the body resists treatment).
- You are not also diagnosed with acquired von Willebrand disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.
This trial tests a new antibody treatment (anti-CD38) for children ages 6 to 18 who have had low platelets for at least 3 months and did not improve with steroids. The goal is to see if this treatment can safely raise platelet counts.
This trial tests a new medicine, bometase alfa, to stop bleeding in people with a rare bleeding disorder called acquired hemophilia A. The goal is to control active bleeding episodes safely.
This trial tests a gene therapy to help your body produce more of the clotting protein (factor VIII) it's missing. It may reduce or stop the need for regular factor infusions.
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
This trial tests an investigational antibody (anti-CD38) for older adults with ITP that hasn't improved with standard treatments. The goal is to see if this antibody can safely raise platelet counts and reduce bleeding risk.
Hear when a new Acquired Hemophilia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.